title: Early predictive value of non-response to docetaxel in neoadjuvant chemotherapy in breast cancer using 18F-FDG-PET.
abstract: BACKGROUND
  The aim of this prospective study of patients with breast cancer was to identify non-responders to docetaxel in neoadjuvant chemotherapy (NCT) using fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG-PET).
  
  
  METHODS
  We analyzed the maximum standardized uptake value (SUVmax) of (18)F-FDG-PET before and after the first course and the reduction rate in tumor size shown by magnetic resonance imaging (MRI) before the first and after the fourth course of docetaxel.
  
  
  RESULTS
  None of the eight patients (0%) whose SUVmax decrease was less than 18% revealed a clinical partial response or clinical complete response; Seven out of the sixteen patients (44%) with an SUVmax decrease over 45% achieved a complete response.
  
  
  CONCLUSIONS
  An SUVmax reduction rate less than 18% is observed in patients with breast cancer after the first course of docetaxel in NCT and may be indicator of non-response to docetaxel.
authors.affiliation: Department of Breast Oncology, Gunma Prefectural Cancer Center, 617-1 Takabayashinishi-cho, Ota City, Gunma, Japan, 373-8550. hiralyto@gmail.com.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Hirakata
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yanagita
authors.forename: Tomomi
authors.initials: T
authors.lastname: Fujisawa
authors.forename: Takaaki
authors.initials: T
authors.lastname: Fujii
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Horikoshi
authors.forename: Nariyuki
authors.initials: N
authors.lastname: Oya
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Akiyoshi
authors.forename: Misa
authors.initials: M
authors.lastname: Iijima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuwano
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D000077143:Docetaxel; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D043823:Taxoids; D019788:Fluorodeoxyglucose F18; D000077143:Docetaxel
keywords: 18F-FDG-PET; breast cancer; docetaxel; neoadjuvant chemotherapy; non-responders